Close the book on another potential Alzheimer’s therapeutic. The large TOMMORROW Alzheimer’s prevention study failed an interim futility analysis and will shut down, Takeda Pharmaceutical Company Ltd. announced in a press release today. TOMMORROW tested the ability of the drug pioglitazone to delay progression to mild cognitive impairment in people at genetic risk for Alzheimer’s disease. The company cited an “inadequate treatment effect” of pioglitazone for its decision, but did not provide numbers. Robert Alexander at Takeda said that the company hopes to release full findings later this year when analysis has been completed.
Others in the field expressed disappointment at the results but not surprise. “It’s a sad day for all who are interested in AD prevention,” John Breitner at McGill University, Montreal, wrote to Alzforum. Paul Aisen at the University of Southern California, San Diego, agreed. He added, “I am sure a full analysis of the data collected will nonetheless advance the field; we always learn from studies whether positive or negative.”
TOMMORROW is the first of the current generation of Alzheimer’s prevention studies to report results. It differs from most others in important aspects, including how it selected participants, measured outcome, and in its choice of drug (Aug 2013 conference news; Dec 2014 conference news).
“These key differences in design make it difficult to say if the negative results from the TOMMORROW trial are likely to extend to the other prevention trials,” Gad Marshall at Brigham and Women’s Hospital, Boston, wrote to Alzforum (see comment below). Others concurred. “This does not forecast a bad outcome for other trials, but also does not point to a clear path for success,” said Jeffrey Cummings at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, who ran one of the clinical sites for the trial.
TOMMORROW enrolled 3,494 cognitively normal participants based on their ApoE and TOMM40 genotype. Alexander noted that to find them, researchers at the 50 clinical sites had to screen about 25,000 people. “We learned a lot about how to identify participants and motivate them to remain in a trial over a long period of time,” he added. Takeda presented some data about the trial’s parameters and retention last December at CTAD and will present a fuller picture this July at AAIC.
One of the study’s goals was to test how well the genetic algorithm succeeded at identifying the people most at risk for progression to MCI, and those data are still being collected, Alexander said. The algorithm applies a controversial finding that a long poly-T repeat in the mitochondrial TOMM40 gene lowers the age of AD onset by about seven years (Jul 2010 conference news; Roses et al., 2010).
Unlike other current prevention trials, TOMMORROW did not test an anti-amyloid therapy. Pioglitazone and related compounds such as rosiglitazone are diabetes drugs that had been abandoned for symptomatic AD treatment based on negative trials, although they did appear to improve brain metabolism, which falters in early AD (Dec 2002 webinar; Sep 2010 news; Dec 2012 news).
TOMMORROW’s outcome measure diverged from those of other ongoing prevention trials in that it used time to progression to MCI-AD, rather than measuring cognitive decline. “[That] is a tough [outcome] to achieve and usually requires a lot more power. All of the other prevention trials use a sensitive global cognitive measure with a continuous score, or a combination of a cognitive measure and progression to MCI,” Marshall wrote. Aisen stressed this as well, noting, “There is no clear line dividing normal cognitive status from MCI, so this endpoint requires the definition and operationalization of a somewhat artificial construct.”
Takeda ran the TOMMORROW study in partnership with Zinfandel Pharmaceuticals, a start-up founded by the late Allen Roses of Duke University. In 1993, Roses discovered the effect of ApoE4 on Alzheimer’s risk, which was widely confirmed. Ann Saunders, who heads Zinfandel and was married to Roses, told Alzforum the company is exploring other opportunities in AD research, though Zinfandel does not have a website describing preclinical or clinical programs. In the meantime, Zinfandel remains committed to sharing the data from the TOMMORROW study with the scientific community, Saunders said.
Other researchers look forward to mining the data. “I am hopeful that the field will be able to leverage these learnings to inform the design of Alzheimer’s prevention trials moving forward,” Jessica Langbaum at Banner Alzheimer’s Institute in Phoenix wrote to Alzforum (see comment below).—Madolyn Bowman Rogers
- Clinical Trials Roundup: Broadening the Lines of Attack
- From Shared CAP, Secondary Prevention Trials Are Off and Running
- Honolulu: Tomm40 Reported to Track With Brain Atrophy, Cognition
- Trial Updates: B Vitamin Back in Vogue? Diabetes Drug Less Sweet
- Can Phagocytosis, Memory Effects Revive Diabetes Meds?
- Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2010 Oct;10(5):375-84. Epub 2009 Dec 22 PubMed.
No Available Further Reading